Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia

Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Schizophrenia bulletin 2023-09, Vol.49 (5), p.1161-1173
Hauptverfasser: Bershad, Anya K, de Wit, Harriet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1173
container_issue 5
container_start_page 1161
container_title Schizophrenia bulletin
container_volume 49
creator Bershad, Anya K
de Wit, Harriet
description Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia. Study Design In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides. Study Results We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia. Conclusions Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.
doi_str_mv 10.1093/schbul/sbad094
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/schbul/sbad094</oup_id><sourcerecordid>2829706135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</originalsourceid><addsrcrecordid>eNqFkUFP3DAQRi1UBFvolSPKsRwCHseOEy4IQVuQoCBBz9Zk4iWusnGwk5W2v560u6By4jTSzJs3I32MHQA_Bl5mJ5GaamxPYoU1L-UWm4GWKgXN4RObcVXkqc5B7rLPMf7mHGSZix22m-lMFYVQM0YPnhy2yX1cUeP7BsMCybf-aXWa_PRL2ybnfR88UmNjMvjkMVgckks7d-SGmLgu2Qhu_eCWODjf_WtS4_5MumA7h_tse45ttF82dY_9-v7t8eIqvbn7cX1xfpOSFGpIoZKVUiCxhFIhUjXPbSbqqqhqkrquIStUzvNaaxSYE_FCg7ZacC0ACHS2x87W3n6sFrYm2w0BW9MHt8CwMh6deT_pXGOe_NIAl0UmtZwMXzeG4J9HGwezcJFs22Jn_RiNKESpeQ6ZmtDjNUrBxxjs_O0OcPM3GrOOxmyimRYO___uDX_NYgKO1oAf-49kL_SxnQQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2829706135</pqid></control><display><type>article</type><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bershad, Anya K ; de Wit, Harriet</creator><creatorcontrib>Bershad, Anya K ; de Wit, Harriet</creatorcontrib><description>Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia. Study Design In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides. Study Results We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia. Conclusions Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</description><identifier>ISSN: 0586-7614</identifier><identifier>ISSN: 1745-1701</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/schbul/sbad094</identifier><identifier>PMID: 37358825</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Apathy ; Humans ; Motivation ; N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use ; Psychopharmacology ; Schizophrenia ; Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</subject><ispartof>Schizophrenia bulletin, 2023-09, Vol.49 (5), p.1161-1173</ispartof><rights>Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2023. 2023</rights><rights>Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2023.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</citedby><cites>FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</cites><orcidid>0000-0002-3011-3730 ; 0000-0002-7211-8994</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483474/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483474/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,1579,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37358825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bershad, Anya K</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia. Study Design In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides. Study Results We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia. Conclusions Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</description><subject>Adult</subject><subject>Apathy</subject><subject>Humans</subject><subject>Motivation</subject><subject>N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use</subject><subject>Psychopharmacology</subject><subject>Schizophrenia</subject><subject>Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</subject><issn>0586-7614</issn><issn>1745-1701</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFP3DAQRi1UBFvolSPKsRwCHseOEy4IQVuQoCBBz9Zk4iWusnGwk5W2v560u6By4jTSzJs3I32MHQA_Bl5mJ5GaamxPYoU1L-UWm4GWKgXN4RObcVXkqc5B7rLPMf7mHGSZix22m-lMFYVQM0YPnhy2yX1cUeP7BsMCybf-aXWa_PRL2ybnfR88UmNjMvjkMVgckks7d-SGmLgu2Qhu_eCWODjf_WtS4_5MumA7h_tse45ttF82dY_9-v7t8eIqvbn7cX1xfpOSFGpIoZKVUiCxhFIhUjXPbSbqqqhqkrquIStUzvNaaxSYE_FCg7ZacC0ACHS2x87W3n6sFrYm2w0BW9MHt8CwMh6deT_pXGOe_NIAl0UmtZwMXzeG4J9HGwezcJFs22Jn_RiNKESpeQ6ZmtDjNUrBxxjs_O0OcPM3GrOOxmyimRYO___uDX_NYgKO1oAf-49kL_SxnQQ</recordid><startdate>20230907</startdate><enddate>20230907</enddate><creator>Bershad, Anya K</creator><creator>de Wit, Harriet</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3011-3730</orcidid><orcidid>https://orcid.org/0000-0002-7211-8994</orcidid></search><sort><creationdate>20230907</creationdate><title>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</title><author>Bershad, Anya K ; de Wit, Harriet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-1b4b5514a9195aacbf6e32db8bdc47dd1385606d77a2a6cc08717e7207211c173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Apathy</topic><topic>Humans</topic><topic>Motivation</topic><topic>N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use</topic><topic>Psychopharmacology</topic><topic>Schizophrenia</topic><topic>Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bershad, Anya K</creatorcontrib><creatorcontrib>de Wit, Harriet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bershad, Anya K</au><au>de Wit, Harriet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>2023-09-07</date><risdate>2023</risdate><volume>49</volume><issue>5</issue><spage>1161</spage><epage>1173</epage><pages>1161-1173</pages><issn>0586-7614</issn><issn>1745-1701</issn><eissn>1745-1701</eissn><abstract>Abstract Background and Hypothesis Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs on social motivation in healthy volunteers that may be relevant to patients. The aim of this review is to synthesize these results in an effort to identify novel directions for the development of medications to treat reduced social motivation in schizophrenia. Study Design In this article, we review pharmacologic challenge studies addressing the acute effects of psychoactive drugs on social motivation in healthy volunteers and consider how these findings may be applied to deficits in social motivation in schizophrenia. We include studies testing amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis, serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides. Study Results We report that amphetamines, MDMA, and some opioid medications enhance social motivation in healthy adults and may represent promising avenues of investigation in schizophrenia. Conclusions Given the acute effects of these drugs on behavioral and performance-based measures of social motivation in healthy volunteers, they may be particularly beneficial as an adjunct to psychosocial training programs in patient populations. It remains to be determined how these medications affect patients with deficits in social motivation, and in which contexts they may be most effectively administered.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37358825</pmid><doi>10.1093/schbul/sbad094</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-3011-3730</orcidid><orcidid>https://orcid.org/0000-0002-7211-8994</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0586-7614
ispartof Schizophrenia bulletin, 2023-09, Vol.49 (5), p.1161-1173
issn 0586-7614
1745-1701
1745-1701
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10483474
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central; Alma/SFX Local Collection
subjects Adult
Apathy
Humans
Motivation
N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use
Psychopharmacology
Schizophrenia
Theme: Approaches to Studying and Improving Social Motivation in Schizophrenia
title Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A19%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Social%20Psychopharmacology:%20Novel%20Approaches%20to%20Treat%20Deficits%20in%20Social%20Motivation%20in%20Schizophrenia&rft.jtitle=Schizophrenia%20bulletin&rft.au=Bershad,%20Anya%20K&rft.date=2023-09-07&rft.volume=49&rft.issue=5&rft.spage=1161&rft.epage=1173&rft.pages=1161-1173&rft.issn=0586-7614&rft.eissn=1745-1701&rft_id=info:doi/10.1093/schbul/sbad094&rft_dat=%3Cproquest_pubme%3E2829706135%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2829706135&rft_id=info:pmid/37358825&rft_oup_id=10.1093/schbul/sbad094&rfr_iscdi=true